Radar-based sensors seem to be having a moment at CES, especially in tech meant for people to keep tabs on their aging family ...

A federal grand jury indicted thirteen Chinese nationals, including four who lived in Des Moines, in a multistate scheme to steal and resell cooking oil. Investigators said members of the group drove ...

The first victim of the deadly school shooting at Brown University has been identified as a sophomore student and vice president of the school’s college Republican club, Ella Cook, according to her ...

Ella Cook, a 19-year-old sophomore from Mountain Brook, Ala., was a gifted pianist and spoke fluent French, a classmate said. By Jenna Russell and Lauren McCarthy Growing up in suburban Mountain Brook ...

The two people who were killed in a shooting at Brown University on Saturday have been identified as students Ella Cook and Mukhammad Aziz Umurzokov. The shooting took place in a classroom on the ...

Mitsui OSK Lines and Titan Clean Fuels have completed a first combined bunkering of both LNG and liquefied biomethane (bio-LNG) under a new term contract for the Japanese shipowner’s car carrier fleet ...

Sabrina Karl has over two decades of experience writing about savings, CDs, and other banking topics. She is currently a full-time staff writer at Investopedia and one of the country's top experts on ...

Gas prices have continued falling in many states across the country this week, including Arizona, California, Oregon and Washington—where drivers pay the highest prices at the pump. However, in some ...

- NKT5097 is designed to selectively degrade CDK2/4 while sparing CDK1/6/7/9, enabling deep pathway inhibition - WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical ...

WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to bring transformative ...

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported ...

- NKT5097 is designed to selectively degrade CDK2/4 while sparing CDK1/6/7/9, enabling deep pathway inhibition - NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on ...